Drug Makers Warn Deregulation Reversal Will Cause Medicine Shortages

The Pakistan Pharmaceutical Manufacturers Association has issued a formal warning that any reversal of the government's pharmaceutical deregulation policy would trigger critical shortages of essential medicines across the country. The industry body argued that price deregulation has been fundamental to sustaining local production capacity and ensuring consistent supply chains for both generic and branded medications.

The PPMA stated that reimposing price controls or rolling back market liberalisation measures would make it financially unviable for manufacturers to continue producing a range of essential drugs, particularly those with thin margins. The association pointed to historical precedent in which rigid price controls precipitated acute shortages that affected millions of patients.

The warning comes amid reported pressure from consumer welfare advocates and some quarters within government to revisit the deregulation framework in response to rising drug prices. Industry representatives have offered to engage in structured dialogue with regulators to address affordability concerns without dismantling the policy architecture.

Public health stakeholders have responded cautiously, acknowledging the manufacturers' concerns while maintaining that unchecked price deregulation has placed essential medicines beyond the reach of lower income patients. The debate sets up a significant policy confrontation between the health ministry, industry, and consumer groups.